Program
alirocumab
Also written as “Alirocumab”, “alirocumab SAR236553 (REGN727)” and “Alirocumab SAR236553 (REGN727)”.
Its studies are mostly in Hypercholesterolemia · Hyperlipoproteinemia Type II · Coronary Artery Disease · Homozygous Familial Hypercholesterolemia · Atherosclerosis, led by 3 companies.
Drug pageAlirocumab: every studyAll 78 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanofiits history only | 300 open or running | phase 4since Dec 24, 2015 | Feb 1, 2011 | none ahead |
| Regeneron Pharmaceuticals | 161 open or running | phase 4since Oct 28, 2016 | Nov 20, 2009 | Dec 29, 2026phase 2 · NCT07477704 |
| Kobe Universityits history only | 20 open or running | phase 4since May 7, 2018 | May 7, 2018 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Regeneron Pharmaceuticals only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 20, 2009First study: phase 1 study in HealthyFirst studyNCT01026597 · 40 enrolled · United States
- Feb 22, 2010Phase 1 study in Healthy VolunteersNCT01074372 · 32 enrolled · United States
- Jul 9, 2010Phase 1 study in HypercholesterolemiaNCT01161082 · 72 enrolled · United States
- Dec 23, 2010Phase 2 study in HypercholesterolemiaNCT01266876 · 77 enrolled · United States, Canada
- Mar 27, 2012Phase 2 study in HypercholesterolemiaNCT01576484 · 58 enrolled · United States, Canada
- May 22, 2012Phase 2 study in HypercholesterolemiaNCT01604824 · 23 enrolled · United States, France
- Oct 8, 20122 phase 3 studiesNCT01709513, NCT01709500
- Nov 9, 20122 phase 3 studies in HypercholesterolemiaNCT01730053, NCT01730040
- Aug 19, 2013Phase 3 study in HypercholesterolemiaNCT01926782 · 803 enrolled · United States, Bulgaria, Canada and more
- Dec 22, 2014Phase 3 study in Heterozygous Familial HypercholesterolemiaNCT02326220 · 62 enrolled · United States, Germany
- Oct 28, 2016Phase 4 study in HypercholesterolemiaNCT02957682 · 2,176 enrolled · United States, Bulgaria, Chile and more
- May 15, 2017Phase 3 study in Homozygous Familial HypercholesterolemiaNCT03156621 · 69 enrolled · United States, Austria, Canada and more
- Sep 6, 2018Phase 4 study in Heterozygous Familial HypercholesterolemiaNCT03694197 · 1,389 enrolled · United States, Bulgaria, Estonia and more
- Mar 12, 2026Phase 2 study in HypercholesterolemiaNCT07477704 · 438 enrolled · United States
Ahead
- Dec 29, 2026Primary completion: phase 2 study in HypercholesterolemiaNCT07477704
TargetBeta
“A human immunoglobulin G1 (IgG1) monoclonal antibody directed against human proprotein convertase subtilisin/kexin type 9 (PCSK9), that can be used in the treatment of hypercholesterolemia”NCIt, by rule
“Subtilisin/kexin type 9 inhibitor”ChEMBL 37, by rule
Other programs on PCSK9
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| evolocumabrule | Amgen | phase 4 | 45 |
| inclisiranrule | Novartis | phase 4 | 37 |
| lerodalcibeprule | lib-therapeutics-llc | phase 3 | 14 |
| tafolecimabrule | Innovent Biologics | phase 3 | 8 |
| recaticimabrule | Jiangsu HengRui Medicine | phase 3 | 7 |
| QLC7401rule | Qilu Pharmaceutical | phase 3 | 5 |
| SYH2053rule | CSPC Pharmaceutical Group | phase 3 | 5 |
| SAL003rule | Shenzhen Salubris Pharmaceuticals | phase 3 | 3 |
| VERVE-102 | Eli Lilly | phase 2 | 2 |
| DNV001rule | hangzhou-dinovate-biotech-co-ltd | phase 2 | 1 |
| RBD7022rule | Qilu Pharmaceutical | phase 1 | 2 |
Studies
All 16 Regeneron Pharmaceuticals leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07477704Hypercholesterolemia · United States | 2 | Active, not recruiting | Dec 29, 2026 | 438 |
| NCT03694197Heterozygous Familial Hypercholesterolemia · United States, Bulgaria, Estonia and more | 4 | Terminated | Apr 8, 2020 | 1,389 |
| NCT03156621Homozygous Familial Hypercholesterolemia · United States, Austria, Canada and more | 3 | Completed | Sep 27, 2019 | 69 |
| NCT02957682Hypercholesterolemia · United States, Bulgaria, Chile and more | 4 | Completed | Mar 5, 2020 | 2,176 |
| NCT02326220Heterozygous Familial Hypercholesterolemia · United States, Germany | 3 | Completed | Jan 31, 2016 | 62 |
| NCT01926782Hypercholesterolemia · United States, Bulgaria, Canada and more | 3 | Completed | Sep 2014 | 803 |
| NCT01730053Hypercholesterolemia · United States, Australia, Canada and more | 3 | Completed | Apr 30, 2014 | 305 |
| NCT01730040Hypercholesterolemia · United States, Australia, Canada and more | 3 | Completed | Apr 2014 | 355 |
| NCT01709513Hypercholesterolemia · United States, Austria, Canada and more | 3 | Completed | May 31, 2014 | 314 |
| NCT01709500Heterozygous Familial Hypercholesterolemia · Czech Republic, Netherlands, Norway and more | 3 | Completed | May 2014 | 249 |
| NCT01604824Hypercholesterolemia · United States, France | 2 | Completed | Jun 2, 2014 | 23 |
| NCT01576484Hypercholesterolemia · United States, Canada | 2 | Completed | Dec 22, 2016 | 58 |
| NCT01266876Hypercholesterolemia · United States, Canada | 2 | Completed | Nov 2011 | 77 |
| NCT01161082Hypercholesterolemia · United States | 1 | Completed | May 2011 | 72 |
| NCT01074372Healthy Volunteers · United States | 1 | Completed | Nov 2010 | 32 |
| NCT01026597Healthy · United States | 1 | Completed | Oct 2010 | 40 |
How it is read
Names in the registry
- “Alirocumab”, 28 entries
- “alirocumab SAR236553 (REGN727)”, 8 entries
- “Alirocumab SAR236553 (REGN727)”, 2 entries
- “alirocumab”, 2 entries
- “REGN727”, 2 entries
Conditions, from the studies’ own filings
- Hypercholesterolemia, 39 studies
- Hyperlipoproteinemia Type II, 2 studies
- Coronary Artery Disease, 2 studies
- Homozygous Familial Hypercholesterolemia, 1 study
- Atherosclerosis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.